Significant advancements in NSCLC treatment! SCRI's Dr. Robert Jotte presents how Adagrasib shows improvement in PFS and ORR over Docetaxel in previously treated patients. Watch his detailed discussion on ecancer: https://lnkd.in/ghE9E4XP #ASCO24 #NSCLC #CancerResearch #Oncology #Immunotherapy #ClinicalTrials
Great summary. Thanks
Lene Bæksgaard Jensen presents: With new studies on zolbetuximab and the discovery of Claudine 18.2 as a new biomarker, patients with limited treatment options may soon see a significant shift in their care. The KEYNOTE 811 study also brings hope to those with HER-2-positive adenocarcinoma in gastric and gastroesophageal cancer. According to KEYNOTE 811, immunotherapy paired with trastuzumab-based chemotherapy shows remarkable improvements in overall survival and progression-free survival, already gaining approval from the EMA. #ESMO23
Researchers have developed a personalized treatment for advanced prostate cancer that the FDA has fast-tracked after a promising clinical trial. The new therapy, SYNC-T SV-102 by Syncromune Inc., showed that nearly 40% of participants had complete cancer remission. This treatment targets metastatic castration-resistant prostate cancer (mCRPC), stimulating the immune system to attack the cancer. In trials, 85% of participants responded positively, a significant improvement over standard treatments. Broader clinical trials are set to begin later this year. Read more: https://lnkd.in/dpK6gpyv #medical #healthcare #oncology #cancerresearch #immunesystem
Is weight loss associated with a subsequent lung cancer diagnosis? We summarize a study in JAMA Network Open that suggests a potential opportunity for early diagnosis https://lnkd.in/eH5Jrs-i #lungcancer #oncology #internalmedicine #weightloss
🔬 Exciting Updates from ASCO 2024 on Renal Cancer! 🔬 Dear Colleagues, Dr Jérémy Blanc from the Institut Jules Bordet, Brussels shares the latest information regarding biomarkers in RCC from ASCO24 - Biomarker analyses from the CLEAR and KEYNOTE-426 trials. - The potential of KIM-1 as non-invasive marker in RCC patients at increased risk of recurrence after resection. Stay updated on the recent findings on biomarkers in RCC by watching this episode! Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #RenalCancer #ASCO2024 #Oncology #MediMix #ClinicalTrials
🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗨 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 In our latest episode, Prof Emmanuel Seront and Prof Christof Vulsteke provide a detailed analysis of the KEYNOTE-B61 study, a significant leap forward in the treatment of non-clear cell renal cancer, as presented at ASCO. Discover how the combination of lenvatinib and pembrolizumab is setting new standards for patient care, showing promising results beyond its established success in endometrial and clear cell renal cancers. 👇 View all WND GU videos - link in the comments! #MediMix #GUCancer #RenalCancer #OncologyInnovation
❗️ Last chance to register for today’s webinar – Spotlight on antibody–drug conjugates in cancer ❗️ Join Fabrice Barlesi and DIERAS Véronique from 17:30–19:00 (CET) as they discuss the mechanism of action of ADCs as well as the key efficacy and safety data from clinical trials in breast and lung cancer. Our expert panel will also explore current challenges and future directions, such as combining ADCs with other agents. Reserve your place now: https://lnkd.in/ebQfYb52 #ADCs #antibodydrugconjugates #oncology #oncologist #breastcancer #lungcancer #meded #medicaleducation
ESMO 2023 <Merck> First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for ESMO Presidential Symposium Session and official Press Briefings Key data to be presented for KEYTRUDA® (pembrolizumab) in earlier stages of cancer across multiple tumor types, including presentation of overall survival results from KEYNOTE-671, and new and updated data from KEYNOTE-A18, KEYNOTE-522 and KEYNOTE-756 First Phase 3 data from LITESPARK-005 trial highlight potential of WELIREG® (belzutifan) in certain previously treated patients with advanced renal cell carcinoma https://lnkd.in/gB6Nx9pW
It is time to question the binary paradigm of responder vs non-responders as well as the “one size fits all” approach in luminal breast cancer. In this review, we summarize the evidence supporting the choice of neoadjuvant chemotherapy (NACT) vs neoadjuvant endocrine therapy (NET) in HR /HER2- BC, discussing the issues surrounding clinical trial design and proper selection of patients for every treatment. #breastcancer #clinicalresearch #clinicaltrialdesign
It is time to question the binary paradigm of responder vs non-responders as well as the “one size fits all” approach in luminal breast cancer. In this review, we summarize the evidence supporting the choice of neoadjuvant chemotherapy (NACT) vs neoadjuvant endocrine therapy (NET) in HR /HER2- BC, discussing the issues surrounding clinical trial design and proper selection of patients for every treatment. #breastcancer #clinicalresearch #clinicaltrialdesign
We would like to inform you that your post has been successfully published on Oncodaily. Thank you for sharing! https://oncodaily.com/drugs/94021.html